NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
21. November 2023 08:00 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...
NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
06. November 2023 16:03 ET
|
NeuroPace, Inc.
Third quarter 2023 revenue of $16.4 million, an increase of 47% year-over-year Full-year revenue guidance increased to $62.5-$63.5 million, up from $59-$61 million Cash burn reduced to $2.2 million...
NeuroPace Announces RNS System Enhancements Designed to Streamline Care
17. Oktober 2023 16:05 ET
|
NeuroPace, Inc.
- Upgraded nSight Platform Improves Clinicians’ Ability to Track, Review and Evaluate Patient Data - - ‘Simple Set Programming’ Enables Complete Programming Set Transfer Directly to RNS Tablet - -...
NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023
16. Oktober 2023 17:01 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...
NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference
20. September 2023 16:05 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...
NeuroPace to Participate in Upcoming Investor Conferences
24. August 2023 16:05 ET
|
NeuroPace, Inc.
- Wells Fargo 2023 Healthcare Conference - - Morgan Stanley 21st Annual Global Healthcare Conference - - Lake Street Capital Markets 7th Annual Best Ideas Growth Conference - MOUNTAIN VIEW, Calif.,...
NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
08. August 2023 16:03 ET
|
NeuroPace, Inc.
Second quarter 2023 revenue of $16.5 million increased 62% year-over-year Full-year revenue guidance increased to $59-$61 million, up from $52-54 million Cash burn reduced to $4 million in the...
NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market
19. Juli 2023 16:03 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...
NeuroPace to Report Second Quarter 2023 Financial Results on August 8, 2023
18. Juli 2023 16:05 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...
NeuroPace Announces CEO Transition
28. Juni 2023 16:03 ET
|
NeuroPace, Inc.
NeuroPace Appoints Joel Becker as President & CEO Becker Brings a Track Record of Strong Commercial Execution and Deep Medical Device Operating Expertise Mike Favet to leave Company after four...